跳至主要内容
临床试验/NCT03892369
NCT03892369已完成不适用

Physiological Effects of FGF21 in Humans and Its Pathophysiological Role in Alcohol Dependence

University Hospital, Gentofte, Copenhagen2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2019年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
45
试验地点
2
主要终点
Fibroblast growthfactor-21

研究概览

简要总结

Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents with alcohol dependence, and C: 15 healthy matched controls without history of or disposition to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using visuel analogue scale and resting energy expenditure will be evaluated using indirect calorimetry.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Informed consent
  • Caucasian males between 25 and 65 years of age
  • BMI between 19 and 27 kg/m2
  • Normal haemoglobin
  • Normal fasting plasma glucose concentration (< 6 mmol/l) and normal glycated haemoglobin A1c (HbA1c) (< 42 mmol/mol)
  • Participants with a father diagnosed with alcohol dependence (group B):
  • Father diagnosed with alcohol dependence
  • Weekly alcohol intake of less than 14 units of alcohol (of 12 g)
  • Normal Alcohol Use Disorders Identification Test (AUDIT) score
  • Healthy participants (group C):
  • Weekly alcohol intake of less than 14 units of alcohol (of 12 g)
  • Normal AUDIT score

排除标准

  • Liver disease evaluated by plasma alanine aminotransferase (ALAT) > 3 × normal level, an international normalised ratio (INR) below normal values, or biopsy-verified alcoholic liver disease
  • Diabetes mellitus
  • Nephropathy
  • Other diseases the investigator finds disruptive for participation in the study.
  • Participants with a father diagnosed with alcohol dependence (group B):
  • - Former alcohol dependence or abuse
  • Healthy participants (group C):
  • First-degree relatives with diabetes, liver disease and/or alcohol dependence
  • Former alcohol dependence

结局指标

主要结局

Fibroblast growthfactor-21

时间窗: One year

Plasma FGF21 concentrations, a member of the endocrine FGF-family

次要结局

  • Ethanol(One year)
  • Glucose(One year)
  • Insulin and C-peptide(One year)
  • Glucagon(One year)
  • Lipopolysaccharide Binding Protein (LBP)(One year)
  • Tumor Necrosis Factor-alpha (TNF)(One year)
  • Interferon-gamma (INF)(One year)
  • Interleukine-8 (IL-8)(One year)
  • Interleukine-6 (IL-6)(One year)
  • Interleukine-10 (IL-10)(One year)

研究者

发起方
University Hospital, Gentofte, Copenhagen
申办方类型
Other
责任方
Principal Investigator
主要研究者

Filip Krag Knop

Head of Clinical Metabolic Physiology, Principal Investigator, Clinical Professor, PhD, MD

University Hospital, Gentofte, Copenhagen

研究点 (2)

Loading locations...

相似试验